{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:59:26Z","timestamp":1783360766882,"version":"3.54.6"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jtct.2022.10.009","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T04:52:10Z","timestamp":1666155130000},"page":"59.e1-59.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3317-0965","authenticated-orcid":false,"given":"Jack","family":"Badaracco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gitlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.10.009_bib0001","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.10.009_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.10.009_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"for the JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.10.009_bib0004","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.10.009_bib0005","unstructured":"BREYANZI (lisocabtagene maraleucel) [package insert]. Bothell, WA: Juno Therapeutics Inc., a Bristol-Myers Squibb Company. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_breyanzi.pdf. Accessed September 27, 2022."},{"key":"10.1016\/j.jtct.2022.10.009_bib0006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.10.009_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.10.009_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2022.10.009_bib0009","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","article-title":"Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel\u2013treated patients in the TRANSCEND NHL 001 trial","volume":"5","author":"Abramson","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.10.009_bib0010","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2022.10.009_bib0011","unstructured":"YESCARTA (axicabtagene ciloleucel) [package insert]. Santa Monica, CA: Kite Pharma, Inc. Available at: https:\/\/www.fda.gov\/media\/108377\/download. Accessed September 27, 2022."},{"key":"10.1016\/j.jtct.2022.10.009_bib0012","unstructured":"KYMRIAH (tisagenlecleucel) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. Available at: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/kymriah.pdf. Accessed September 27, 2022."},{"key":"10.1016\/j.jtct.2022.10.009_bib0013","unstructured":"US Bureau of Labor Statistics. Consumer Price Indexes (CPI) for medical care 2020. Available at: https:\/\/data.bls.gov\/cgi-bin\/surveymost. Accessed September 27, 2022."},{"key":"10.1016\/j.jtct.2022.10.009_bib0014","unstructured":"Bristol Myers Squibb. Data on file [Burden of Cytokine Release Syndrome (CRS) and Neurotoxicity (NT) in Patients (Pts) With Relapsed\/Refractory Non-Hodgkin Lymphoma (NHL) Receiving Lisocabtagene Maraleucel (liso-cel; JCAR017) in TRANSCEND NHL 001, 2020]."},{"key":"10.1016\/j.jtct.2022.10.009_bib0015","unstructured":"American Hospital Association. Trendwatch Chartbook 2020: supplementary data tables, trends in the overall health care market. Published 2022. Available at: https:\/\/www.aha.org\/system\/files\/media\/file\/2020\/10\/TrendwatchChartbook-2020-Appendix.pdf. Accessed September 27, 2022."},{"key":"10.1016\/j.jtct.2022.10.009_bib0016","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.jtct.2022.10.009_bib0017","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.10.009_bib0018","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722017043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:02Z","timestamp":1763003342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722017043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2666636722017043"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.10.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}